Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 23.57 Million GBP | -22.11% |
| 2023 | 30.27 Million GBP | -21.42% |
| 2022 | 38.52 Million GBP | -21.48% |
| 2021 | 49.05 Million GBP | 456.34% |
| 2020 | 8.81 Million GBP | -16.36% |
| 2019 | 10.54 Million GBP | -27.98% |
| 2018 | 14.63 Million GBP | 108.17% |
| 2017 | 7.03 Million GBP | -33.47% |
| 2016 | 10.56 Million GBP | 43.63% |
| 2015 | 7.35 Million GBP | -23.47% |
| 2014 | 9.61 Million GBP | 77.81% |
| 2013 | 5.4 Million GBP | -25.48% |
| 2012 | 7.25 Million GBP | 52.5% |
| 2011 | 4.75 Million GBP | -26.8% |
| 2010 | 6.5 Million GBP | 19.9% |
| 2009 | 5.42 Million GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 22.25 Million GBP | 0.0% |
| 2024 Q4 | 23.57 Million GBP | 0.0% |
| 2024 Q1 | 22.25 Million GBP | -26.49% |
| 2023 Q4 | 30.27 Million GBP | 0.0% |
| 2023 FY | 30.27 Million GBP | -21.42% |
| 2023 Q3 | 30.27 Million GBP | -21.2% |
| 2023 Q1 | 38.41 Million GBP | -0.28% |
| 2023 Q2 | 38.41 Million GBP | 0.0% |
| 2022 Q3 | 38.52 Million GBP | -13.83% |
| 2022 FY | 38.52 Million GBP | -21.48% |
| 2022 Q2 | 44.7 Million GBP | 0.0% |
| 2022 Q1 | 44.7 Million GBP | -8.88% |
| 2022 Q4 | 38.52 Million GBP | 0.0% |
| 2021 Q4 | 49.05 Million GBP | 0.0% |
| 2021 FY | 49.05 Million GBP | 456.34% |
| 2021 Q3 | 49.05 Million GBP | 54.1% |
| 2021 Q2 | 31.83 Million GBP | 0.0% |
| 2021 Q1 | 31.83 Million GBP | 261.03% |
| 2020 Q4 | 8.81 Million GBP | 0.0% |
| 2020 Q1 | 11.43 Million GBP | 8.46% |
| 2020 FY | 8.81 Million GBP | -16.36% |
| 2020 Q2 | 11.43 Million GBP | 0.0% |
| 2020 Q3 | 8.81 Million GBP | -22.88% |
| 2019 Q3 | 10.54 Million GBP | -14.92% |
| 2019 Q4 | 10.54 Million GBP | 0.0% |
| 2019 Q1 | 12.39 Million GBP | -15.35% |
| 2019 Q2 | 12.39 Million GBP | 0.0% |
| 2019 FY | 10.54 Million GBP | -27.98% |
| 2018 Q2 | 9.67 Million GBP | 0.0% |
| 2018 Q1 | 9.67 Million GBP | 37.63% |
| 2018 FY | 14.63 Million GBP | 108.17% |
| 2018 Q4 | 14.63 Million GBP | 0.0% |
| 2018 Q3 | 14.63 Million GBP | 51.25% |
| 2017 Q1 | 8.87 Million GBP | -16.04% |
| 2017 Q4 | 7.03 Million GBP | 0.0% |
| 2017 Q2 | 8.87 Million GBP | 0.0% |
| 2017 FY | 7.03 Million GBP | -33.47% |
| 2017 Q3 | 7.03 Million GBP | -20.75% |
| 2016 Q1 | 5.99 Million GBP | -18.51% |
| 2016 FY | 10.56 Million GBP | 43.63% |
| 2016 Q4 | 10.56 Million GBP | 0.0% |
| 2016 Q3 | 10.56 Million GBP | 76.25% |
| 2016 Q2 | 5.99 Million GBP | 0.0% |
| 2015 Q4 | 7.35 Million GBP | 0.0% |
| 2015 FY | 7.35 Million GBP | -23.47% |
| 2015 Q3 | 7.35 Million GBP | -11.28% |
| 2015 Q2 | 8.29 Million GBP | 0.0% |
| 2015 Q1 | 8.29 Million GBP | -13.75% |
| 2014 Q3 | 9.61 Million GBP | -7.88% |
| 2014 Q2 | 10.43 Million GBP | 0.0% |
| 2014 Q1 | 10.43 Million GBP | 93.01% |
| 2014 FY | 9.61 Million GBP | 77.81% |
| 2014 Q4 | 9.61 Million GBP | 0.0% |
| 2013 Q4 | 5.4 Million GBP | 0.0% |
| 2013 FY | 5.4 Million GBP | -25.48% |
| 2013 Q2 | 6.32 Million GBP | 0.0% |
| 2013 Q3 | 5.4 Million GBP | -14.51% |
| 2012 Q2 | 5.69 Million GBP | 0.0% |
| 2012 FY | 7.25 Million GBP | 52.5% |
| 2012 Q4 | 7.25 Million GBP | 0.0% |
| 2011 Q4 | 4.75 Million GBP | 0.0% |
| 2011 FY | 4.75 Million GBP | -26.8% |
| 2011 Q2 | 5.49 Million GBP | 0.0% |
| 2010 FY | 6.5 Million GBP | 19.9% |
| 2009 FY | 5.42 Million GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 39.311% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -226.548% |
| SQZ Biotechnologies Company | 107.18 Million USD | 78.005% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -123.384% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 81.894% |
| Mesoblast Limited | 667.9 Million USD | 96.47% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -32479.286% |
| Genus plc | 1.02 Billion USD | 97.709% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1635.631% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -4624.28% |
| Marizyme, Inc. | 22.01 Million USD | -7.09% |
| ContraFect Corporation | 20.67 Million USD | -14.009% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -3660.128% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -5939.46% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -6068.869% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1546.332% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -468.641% |
| MultiCell Technologies, Inc. | 126.22 USD | -18678397.861% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2408.915% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 81.654% |
| EV Biologics, Inc. | 431.71 Thousand USD | -5361.023% |
| Q BioMed Inc. | 3.51 Million USD | -570.627% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 32.983% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2959.26% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -8923.374% |
| Biomind Labs Inc. | 73.81 Thousand USD | -31837.577% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 94.906% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 21.452% |
| Skye Bioscience, Inc. | 11.94 Million USD | -97.447% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -611.618% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -758.453% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1103.97% |
| IMV Inc. | 31.33 Million USD | 24.759% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3329.306% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -805.656% |
| GB Sciences, Inc. | 103.44 Thousand USD | -22691.516% |
| Alpha Cognition Inc. | 2.45 Million USD | -861.434% |
| HST Global, Inc. | 1526.00 USD | -1544854.128% |
| CSL Limited | 38.02 Billion USD | 99.938% |
| Halberd Corporation | 10.13 Thousand USD | -232611.48% |
| Enzolytics Inc. | 361.7 Million USD | 93.482% |
| Resverlogix Corp. | 8.11 Million USD | -190.524% |
| Affymax, Inc. | 7.44 Million USD | -216.754% |
| SYBLEU INC | 330.46 Thousand USD | -7034.125% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1155.458% |
| argenx SE | 4.54 Billion USD | 99.481% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 15.631% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 50.576% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -103389.75% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -163.444% |
| AVAX Technologies, Inc. | 7.37 Million USD | -219.581% |
| Zenith Capital Corp. | 7410.00 USD | -318064.642% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.304% |
| Ember Therapeutics, Inc. | 184.00 USD | -12812943.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -7226.153% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -8920.37% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 94.718% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1527.229% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -679.35% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 55.265% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2440.624% |
| BioStem Technologies, Inc. | 14.56 Million USD | -61.92% |
| ONE Bio Corp. | 70.08 Million USD | 66.361% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -41193.306% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1020506.061% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2286.315% |
| Agentix Corp. | 261.39 Thousand USD | -8919.404% |
| LadRx Corporation | 2.3 Million USD | -921.543% |
| Cell Source, Inc. | 195.17 Thousand USD | -11979.663% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -4805.974% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6567.1% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6567.1% |
| NovAccess Global Inc. | 62.24 Thousand USD | -37774.309% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -3585.731% |
| Itoco Inc. | 1.4 Million USD | -1583.913% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -24546.393% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -22141.509% |
| Kadimastem Ltd | 2.3 Million USD | -923.228% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -30777.23% |
| CytoDyn Inc. | 11.13 Million USD | -111.71% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -16389.942% |
| Mobile Lads Corp. | 52.00 USD | -45338361.538% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -131756.823% |
| Qrons Inc. | 420.00 USD | -5613233.333% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -6016.154% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -4170.086% |
| Rebus Holdings, Inc. | 5000.00 USD | -471420.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -5658.362% |
| International Stem Cell Corporation | 5.39 Million USD | -337.403% |
| Bioxytran, Inc. | 137.63 Thousand USD | -17028.991% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -57.154% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -42.204% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -29743.038% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2626.567% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -213.636% |
| Neutra Corp. | 2851.00 USD | -826837.917% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 27.248% |
| PureTech Health plc | 693.97 Million USD | 96.603% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -192.104% |
| IXICO plc | 15.84 Million USD | -48.802% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -184.666% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 77.182% |
| CSL Limited | 38.02 Billion USD | 99.938% |
| Cellectis S.A. | 333.99 Million USD | 92.941% |